|
SensiGen assays run on the proprietary MassARRAY® PCR-MS system developed by Sequenom Inc., and licensed exclusively by SensiGen. The MassARRAY® system is a highly automated, widely established PCR-MS platform capable of identifying more than 30 target sequences in a single reaction and with capacity to process nearly 2,000 samples in a single run. The "attomolar" (10E-18 molar) sensitivity levels of SensiGen's assays represent an unprecedented 2+ orders of magnitude improvement over the current state of the art. Moreover, SensiGen assays can work with any biological medium (blood, urine, tissue, etc.) and readily deliver genotype specific, fully quantitative results, in absolute or relative terms (e.g. “viral load”) as opposed to returning only “positive” or “negative” results in an aggregate sense. SensiGen assays currently in development include: AttoSense™ HPV-G AttoSense™ HPV-Q AttoSense™ Kidney Test EpiSense™ Lupus For more information on the MassARRAY® system from Sequenom, follow this link: www.sequenom.com FOR RESEARCH USE ONLY: These statements have not been evaluated by the FDA. |
|
SensiGen has developed a new type of gene-based molecular diagnostic testing technology, called AttoSense™ and EpiSense™, which have revolutionized the art of molecular level detection. These approaches combine "real-competitive" polymerase chain reaction (rc-PCR) with matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), collectively called PCR-MS, to enable unique, multiplex assays that can reliably and accurately detect as few as one to three target sequences in any biological sample.